Replimune Group, Inc. (REPL)
8.105
+0.08
(+0.93%)
USD |
NASDAQ |
Jan 12, 16:00
8.10
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Research and Development Expense (Quarterly): 57.65M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Rapt Therapeutics, Inc. | 12.03M |
| Olema Pharmaceuticals, Inc. | 39.95M |
| CorMedix, Inc. | 5.098M |
| Verastem, Inc. | 28.99M |
| Anavex Life Sciences Corp. | 7.295M |